We are live on ! Find out more
IDYA icon

IDEAYA Biosciences

207 hedge funds and large institutions have $1.54B invested in IDEAYA Biosciences in 2025 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 104 increasing their positions, 49 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more call options, than puts

Call options by funds: $1.43M | Put options by funds: $585K

112% more repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 49

4% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 25

0.85% more ownership

Funds ownership: 106.39%107.24% (+0.85%)

0% more funds holding

Funds holding: 206207 (+1)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

35% less capital invested

Capital invested by funds: $2.36B → $1.54B (-$821M)

Holders
207
Holders Change
+1
Holders Change %
+0.49%
% of All Funds
2.78%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
26
Increased
104
Reduced
49
Closed
25
Calls
$1.43M
Puts
$585K
Net Calls
+$840K
Net Calls Change
+$525K
Name Holding Trade Value Shares
Change
Change in
Stake
EAM
26
Eventide Asset Management
Massachusetts
$12.6M
Northern Trust
27
Northern Trust
Illinois
$12.3M -$390K -18,323 -2%
Charles Schwab
28
Charles Schwab
California
$11.5M -$194K -9,095 -1%
RA
29
Rosalind Advisors
Ontario, Canada
$11.5M +$14.9M +700,000 New
DCM
30
DAFNA Capital Management
California
$9.65M +$1.93M +90,503 +18%
Millennium Management
31
Millennium Management
New York
$8.97M +$9.05M +424,625 +345%
RG
32
Redmile Group
California
$8.76M -$1.8M -84,700 -14%
Jennison Associates
33
Jennison Associates
New York
$8.63M -$9.54M -447,948 -46%
Two Sigma Investments
34
Two Sigma Investments
New York
$7.68M +$955K +44,804 +11%
Deutsche Bank
35
Deutsche Bank
Germany
$7.66M +$2.01M +94,482 +25%
UBS Group
36
UBS Group
Switzerland
$7.37M +$675K +31,662 +8%
APM
37
Avidity Partners Management
Texas
$7.29M -$14.5M -681,700 -61%
Aberdeen Group
38
Aberdeen Group
United Kingdom
$7.23M +$2.87M +134,582 +44%
MB
39
MPM BioImpact
Massachusetts
$7.05M +$344K +16,126 +4%
Two Sigma Advisers
40
Two Sigma Advisers
New York
$6.77M -$1M -47,000 -10%
Renaissance Technologies
41
Renaissance Technologies
New York
$5.86M +$1.56M +73,333 +26%
New York State Common Retirement Fund
42
New York State Common Retirement Fund
New York
$5.42M
JP Morgan Chase
43
JP Morgan Chase
New York
$5.42M +$1.19M +55,900 +20%
Ensign Peak Advisors
44
Ensign Peak Advisors
Utah
$5.37M -$5.04M -236,573 -42%
Axa
45
Axa
France
$5.31M +$1.58M +74,318 +30%
WP
46
Woodline Partners
California
$5.17M -$5.87M -275,325 -47%
D.E. Shaw & Co
47
D.E. Shaw & Co
New York
$5.05M +$2.72M +127,880 +71%
AG
48
Algert Global
California
$5.02M +$6.53M +306,708 New
UBS AM
49
UBS AM
Illinois
$4.97M -$429K -20,141 -6%
Voloridge Investment Management
50
Voloridge Investment Management
Florida
$4.81M +$145K +6,816 +2%

IDYA Hedge Fund Activity: Q1 2025 in Review

207 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in IDEAYA Biosciences (IDYA) for Q1 2025, worth a combined $1.54B — down 35% from $2.36B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new IDYA positions and 25 closed out — a net gain of 1 holder — while 104 added to existing stakes and 49 trimmed.

The largest buyer was Sofinnova Investments, adding an estimated $33.1M. The largest seller was Goldman Sachs, cutting an estimated $20.1M.

  • 207 institutional investors held IDEAYA Biosciences (IDYA) as of Q1 2025, up from 206 in Q4 2024.
  • Funds reported $1.54B of IDEAYA Biosciences stock for Q1 2025, down 35% quarter-over-quarter.
  • 26 funds opened new IDEAYA Biosciences positions in Q1 2025 and 25 closed out, a net change of +1 holder.
  • The largest IDEAYA Biosciences buyer in Q1 2025 was Sofinnova Investments, an estimated $33.1M added.
  • The largest IDEAYA Biosciences seller in Q1 2025 was Goldman Sachs, an estimated $20.1M sold.

Based on aggregated 13F filings for Q1 2025.